Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts
Year: 2018
Type: review
Abstract: Hepatic fibrosis is characterized by the formation and deposition of excess fibrous connective tissue, leading to progressive architectural tissue remodeling. Irrespective of the underlying noxious trigger, tissue damage induces an inflammatory response involving the local vascular system and the immune system and a systemic mobilization of endocrine and neurological mediators, ultimately leading to the activation of matrix-producing cell populations. Genetic disorders, chronic viral infection, alcohol abuse, autoimmune attacks, metabolic disorders, cholestasis, alterations in bile acid composition or concentration, venous obstruction, and parasite infections are well-established factors that predispose one to hepatic fibrosis. In addition, excess fat and other lipotoxic mediators provoking endoplasmic reticulum stress, alteration of mitochondrial function, oxidative stress, and modifications in the microbiota are associated with non-alcoholic fatty liver disease and, subsequently, the initiation and progression of hepatic fibrosis. Multidisciplinary panels of experts have developed practice guidelines, including recommendations of preferred therapeutic approaches to a specific cause of hepatic disease, stage of fibrosis, or occurring co-morbidities associated with ongoing loss of hepatic function. Here, we summarize the factors leading to liver fibrosis and the current concepts in anti-fibrotic therapies.
Source: F1000Research
Institutions: Universitätsklinikum Aachen, RWTH Aachen University
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: liver fibrosis, non-alcoholic fatty liver disease, lipotoxicity, endoplasmic reticulum stress, mitochondrial dysfunction, oxidative stress, gut microbiota, bile acids, chronic viral hepatitis, alcoholic liver disease, autoimmune liver disease, cholestasis, venous obstruction, parasitic infection, fibrosis staging, antifibrotic therapy, personalized treatment
Open Access status: gold
Estimated APC paid: $1,350
Awards: G1392329581, G4208438675
OpenAlex ID: W2811031628
